CA2461363A1 - 3-pyridyl indoles et indazoles substitues servant d'inhibiteurs de c17,20 lyase - Google Patents

3-pyridyl indoles et indazoles substitues servant d'inhibiteurs de c17,20 lyase Download PDF

Info

Publication number
CA2461363A1
CA2461363A1 CA002461363A CA2461363A CA2461363A1 CA 2461363 A1 CA2461363 A1 CA 2461363A1 CA 002461363 A CA002461363 A CA 002461363A CA 2461363 A CA2461363 A CA 2461363A CA 2461363 A1 CA2461363 A1 CA 2461363A1
Authority
CA
Canada
Prior art keywords
pyridyl
indole
alkyl
bromo
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002461363A
Other languages
English (en)
Inventor
Gaetan H. Ladouceur
Michael J. Burke
Wai C. Wong
Donald Bierer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharmaceuticals Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2461363A1 publication Critical patent/CA2461363A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

L'invention concerne des 3-pyridyl indoles et indazoles substitués, ainsi que des compositions pharmaceutiques contenant ces composés. L'invention concerne également des procédés d'utilisation de 3-pyridyl indoles et indazoles substitués, et de compositions pharmaceutiques contenant ces composés, en tant qu'inhibiteurs de lyases, par ex. de l'enzyme 17.alpha.-hydroxylase-C17,20-lyase. L'invention concerne par ailleurs des procédés de traitement du cancer chez un malade, consistant à administrer à un malade des 3-pyridyl indoles et indazoles substitués, ou une composition pharmaceutique contenant ces composés. Les cancers concernés par le traitement selon l'invention sont par ex. le cancer de la prostate ou le cancer du sein.
CA002461363A 2001-09-26 2002-09-26 3-pyridyl indoles et indazoles substitues servant d'inhibiteurs de c17,20 lyase Abandoned CA2461363A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32499301P 2001-09-26 2001-09-26
US60/324,993 2001-09-26
PCT/US2002/030482 WO2003027094A2 (fr) 2001-09-26 2002-09-26 3-pyridyl indoles et indazoles substitues servant d'inhibiteurs de c17,20 lyase

Publications (1)

Publication Number Publication Date
CA2461363A1 true CA2461363A1 (fr) 2003-04-03

Family

ID=23265979

Family Applications (2)

Application Number Title Priority Date Filing Date
CA002461363A Abandoned CA2461363A1 (fr) 2001-09-26 2002-09-26 3-pyridyl indoles et indazoles substitues servant d'inhibiteurs de c17,20 lyase
CA002461360A Abandoned CA2461360A1 (fr) 2001-09-26 2002-09-26 Thiazoles 3-pyridyle ou 4-isoquinolinyle utilises comme inhibiteurs de lyase c17,20

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA002461360A Abandoned CA2461360A1 (fr) 2001-09-26 2002-09-26 Thiazoles 3-pyridyle ou 4-isoquinolinyle utilises comme inhibiteurs de lyase c17,20

Country Status (5)

Country Link
EP (2) EP1432706A2 (fr)
JP (2) JP2005532983A (fr)
AU (2) AU2002340010A1 (fr)
CA (2) CA2461363A1 (fr)
WO (8) WO2003027094A2 (fr)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4160295B2 (ja) * 2000-12-08 2008-10-01 武田薬品工業株式会社 ３−ピリジル基を有する置換チアゾール誘導体、その製造法および用途
CA2431171A1 (fr) * 2000-12-08 2002-06-13 Takeda Chemical Industries, Ltd. Derives thiazole substitues porteurs de groupes 3-pyridyl, procede d'elaboration et leur utilisation
US20040147561A1 (en) * 2002-12-27 2004-07-29 Wenge Zhong Pyrid-2-one derivatives and methods of use
US7244739B2 (en) * 2003-05-14 2007-07-17 Torreypines Therapeutics, Inc. Compounds and uses thereof in modulating amyloid beta
ES2222827B1 (es) * 2003-07-30 2006-03-01 Laboratorios Del Dr. Esteve, S.A. Derivados de 5-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos.
CN101675928A (zh) * 2003-11-14 2010-03-24 沃泰克斯药物股份有限公司 可用作atp-结合弹夹转运蛋白调控剂的噻唑和噁唑
AU2005232745A1 (en) 2004-04-13 2005-10-27 Astellas Pharma Inc. Polycyclic pyrimidines as potassium ion channel modulators
JP4602686B2 (ja) * 2004-04-15 2010-12-22 広栄化学工業株式会社 ２，６−ジハロゲノ−４−アリールピリジン類の製造法
EP1815206B1 (fr) 2004-10-13 2016-04-06 PTC Therapeutics, Inc. Composes de suppression de non-sens et procedes de leur utilisation
DK1802579T3 (da) * 2004-10-20 2014-01-20 Merck Serono Sa Derivater af 3-arylaminopyridin
WO2006051723A1 (fr) * 2004-11-09 2006-05-18 Kaneka Corporation Méthode de synthèse de 1-halogéno-3-aryl-2-propanone
GB0428514D0 (en) * 2004-12-31 2005-02-09 Prosidion Ltd Compounds
CN101142185A (zh) * 2005-01-19 2008-03-12 比奥里波克斯公司 用于炎症治疗的吲哚
US8088806B2 (en) 2005-05-09 2012-01-03 Achillion Pharmaceuticals, Inc. Thiazole compounds and methods of use
CN101233119A (zh) * 2005-07-29 2008-07-30 4Sc股份有限公司 新型杂环NF-κB抑制剂
FR2889526B1 (fr) 2005-08-04 2012-02-17 Aventis Pharma Sa 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation
US7947707B2 (en) * 2005-10-07 2011-05-24 Kissei Pharmaceutical Co., Ltd. Nitrogenated heterocyclic compound and pharmaceutical composition comprising the same
TWI385169B (zh) 2005-10-31 2013-02-11 Eisai R&D Man Co Ltd 經雜環取代之吡啶衍生物及含有彼之抗真菌劑
JP2009523701A (ja) * 2005-12-28 2009-06-25 武田薬品工業株式会社 縮合複素環化合物およびその用途
WO2007082808A2 (fr) * 2006-01-18 2007-07-26 F. Hoffmann-La Roche Ag Thiazoles en tant qu'inhibiteurs de 11 beta-hsd1
BRPI0706411A2 (pt) * 2006-01-24 2011-03-29 Lilly Co Eli composto, composição farmacêutica, método de preparação de um indol ou um sal farmaceuticamente aceitável do mesmo, e, uso de um composto
PT2001849E (pt) 2006-03-29 2015-02-05 Hoffmann La Roche Derivados de piridina e pirimidina como antagonistas de r2mglu
US7652018B2 (en) 2006-08-15 2010-01-26 Wyeth Llc Imidazolidin-2-one derivatives useful as PR modulators
WO2008021337A1 (fr) 2006-08-15 2008-02-21 Wyeth Dérivés oxazinan-2-one utiles comme modulateurs pr
WO2008021338A2 (fr) 2006-08-15 2008-02-21 Wyeth Dérivés d'oxazolidone tricycliques utiles en tant que modulateurs du récepteur de la progestérone
US7649007B2 (en) 2006-08-15 2010-01-19 Wyeth Llc Oxazolidine derivatives as PR modulators
ATE534642T1 (de) * 2006-09-21 2011-12-15 Eisai R&D Man Co Ltd Durch einen heteroarylring substituiertes pyridinderivat und antipilzmittel, das dieses enthält
EP2065377B1 (fr) 2006-09-21 2011-11-23 Eisai R&D Management Co., Ltd. Dérivé de pyridine substitué par un cycle hétéroaryle, et agent antifongique le comprenant
WO2008042898A2 (fr) 2006-10-02 2008-04-10 Cortendo Invest, Ab Énantiomère de cétoconazole chez les êtres humains
US8466154B2 (en) 2006-10-27 2013-06-18 The Board Of Regents Of The University Of Texas System Methods and compositions related to wrapping of dehydrons
US9187485B2 (en) 2007-02-02 2015-11-17 Baylor College Of Medicine Methods and compositions for the treatment of cancer and related hyperproliferative disorders
CN101801964A (zh) 2007-05-22 2010-08-11 艾其林医药公司 杂芳基取代的噻唑及其作为抗病毒剂的用途
CA2699980C (fr) 2007-08-13 2015-06-02 Divergence, Inc. Compositions et procedes pour lutter contre les nematodes
BRPI0818658A2 (pt) 2007-10-09 2015-04-14 Merck Patent Ges Mit Beschränkter Haftung Derivados de piridina úteis como ativadores de glicoquinase
US8513287B2 (en) 2007-12-27 2013-08-20 Eisai R&D Management Co., Ltd. Heterocyclic ring and phosphonoxymethyl group substituted pyridine derivatives and antifungal agent containing same
BRPI0906838A2 (pt) 2008-01-11 2015-07-14 Novartis Ag Pirimidinas como inibidores de quinase
WO2009094224A1 (fr) 2008-01-25 2009-07-30 Millennium Pharmaceuticals, Inc. Thiophènes et leurs utilisations
ES2655305T3 (es) 2008-02-08 2018-02-19 Shiseido Company, Ltd. Agente para blanqueamiento de la piel
US9447049B2 (en) 2010-03-01 2016-09-20 University Of Tennessee Research Foundation Compounds for treatment of cancer
US9029408B2 (en) 2008-06-16 2015-05-12 Gtx, Inc. Compounds for treatment of cancer
DK2959900T3 (en) 2008-06-16 2017-06-26 Univ Tennessee Res Found CONNECTION TO TREATMENT OF CANCER
US8822513B2 (en) 2010-03-01 2014-09-02 Gtx, Inc. Compounds for treatment of cancer
AU2009282567B2 (en) * 2008-08-20 2014-10-02 Merck Sharp & Dohme Corp. Substituted pyridine and pyrimidine derivatives and their use in treating viral infections
US8536185B2 (en) 2008-09-22 2013-09-17 Cayman Chemical Company, Incorporated Multiheteroaryl compounds as inhibitors of H-PGDS and their use for treating prostaglandin D2 mediated diseases
US9090601B2 (en) 2009-01-30 2015-07-28 Millennium Pharmaceuticals, Inc. Thiazole derivatives
CN102395585A (zh) 2009-01-30 2012-03-28 米伦纽姆医药公司 杂芳基化合物和其作为pi3k抑制剂的用途
US8796314B2 (en) 2009-01-30 2014-08-05 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
WO2010106290A1 (fr) * 2009-03-19 2010-09-23 Sanofi-Aventis Derives d'indazole inhibiteurs d'hsp90, compositions les contenant et utilisation
EP2592071B1 (fr) * 2009-10-29 2019-09-18 Bristol-Myers Squibb Company Composés hétérocycliques tricycliques
WO2011051198A2 (fr) * 2009-10-30 2011-05-05 Bayer Cropscience Ag Dérivés de pyridine en tant qu'agents phytoprotecteurs
DE102009058280A1 (de) * 2009-12-14 2011-06-16 Merck Patent Gmbh Thiazolderivate
EP3064204A1 (fr) 2010-03-01 2016-09-07 GTx, Inc. Composes pour le traitement du cancer
CN103140490A (zh) 2010-07-15 2013-06-05 百时美施贵宝公司 氮杂吲唑化合物
AU2011285724B2 (en) 2010-08-04 2015-01-22 Pellficure Pharmaceuticals, Inc. Combination therapy for the treatment of prostate carcinoma
US9062038B2 (en) 2010-08-11 2015-06-23 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
EP2603216A4 (fr) 2010-08-11 2013-12-18 Millennium Pharm Inc Hétéroaryles et utilisations
CN103153300A (zh) 2010-08-11 2013-06-12 米伦纽姆医药公司 杂芳基化合物和其用途
SG189396A1 (en) 2010-10-13 2013-05-31 Millennium Pharm Inc Heteroaryls and uses thereof
CN103270029B (zh) * 2010-10-22 2016-01-20 拜耳知识产权有限责任公司 作为农药的杂环化合物
CA2816088A1 (fr) * 2010-10-28 2012-05-03 Viamet Pharmaceuticals, Inc. Composes inhibiteurs de metalloenzymes
EP2638041B1 (fr) 2010-11-12 2015-07-22 Bristol-Myers Squibb Company Dérivés azaindole substitués
GB2485404A (en) * 2010-11-15 2012-05-16 Nat Univ Ireland Metal-complexed pyridyl-substituted tetrazole compounds and their use in treating cancer
CN102675286B (zh) * 2011-03-07 2015-08-19 中国科学院上海药物研究所 一类吲唑类化合物及其制备方法、用途和药物组合物
CN103649073B (zh) 2011-04-28 2016-04-13 诺瓦提斯公司 17α-羟化酶/C17,20-裂合酶抑制剂
WO2012162468A1 (fr) * 2011-05-25 2012-11-29 Janssen Pharmaceutica Nv Dérivés de thiazole en tant qu'inhibiteurs de pro-métalloprotéinases de matrice
EP2760870B1 (fr) 2011-09-27 2016-05-04 Bristol-Myers Squibb Company Composés d'hétéroaryle bicycliques substitués
WO2014055595A1 (fr) 2012-10-05 2014-04-10 Merck Sharp & Dohme Corp. Composés d'indoline utilisés comme inhibiteurs de l'aldostérone synthase et applications s'y rapportant
EP2934144B1 (fr) 2012-12-20 2017-07-19 Merck Sharp & Dohme Corp. Composés d'indazole utiles comme inhibiteurs de l'aldostérone synthase
CN109568312A (zh) 2013-03-05 2019-04-05 田纳西大学研究基金会 用于治疗癌症的化合物
EP2968219B1 (fr) 2013-03-14 2019-04-24 Pellficure Pharmaceuticals, Inc. Nouvelle thérapie pour le carcinome de la prostate
CA2960750A1 (fr) 2014-09-12 2016-03-17 Pellficure Pharmaceuticals, Inc. Compositions et methodes de traitement d'un carcinome de la prostate
CA3044812A1 (fr) 2016-10-24 2018-05-03 Pellficure Pharmaceuticals Inc. Compositions pharmaceutiques de 5-hydroxy-2-methylnaphtalene-1, 4-dione
JP7193071B2 (ja) * 2017-02-08 2022-12-20 国立大学法人東海国立大学機構 蛍光発光材料および紫外線吸収剤
CN115087657A (zh) * 2019-12-18 2022-09-20 加利福尼亚大学董事会 Lin28抑制剂和其使用方法
US20210246109A1 (en) * 2020-02-11 2021-08-12 University Of Kentucky Research Foundation Potent and selective inhibitors of cytochrome p450
WO2023049199A1 (fr) * 2021-09-24 2023-03-30 Zeno Management, Inc. Composés azole

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK150068C (da) * 1978-06-02 1987-06-29 Pfizer Analogifremgangsmaade til fremstilling af aminothiazoler
JPS55133366A (en) * 1979-04-05 1980-10-17 Otsuka Pharmaceut Factory Inc Thiazole derivative
US4536505A (en) * 1983-05-17 1985-08-20 Ciba-Geigy Corporation Certain N-(pyridyl) indoles
DE3940476A1 (de) * 1989-12-07 1991-06-13 Bayer Ag Pyridinylpyrimidin-derivate
DE3940477A1 (de) * 1989-12-07 1991-06-13 Bayer Ag Hetaryl-substituierte pyridinylpyrimidin-derivate
JPH04154773A (ja) * 1990-10-15 1992-05-27 Green Cross Corp:The チアゾール誘導体
DE4117560A1 (de) * 1991-05-29 1992-12-03 Bayer Ag Verwendung von pyridinylpyrimidin-derivaten zum schutz technischer materialien
TW223004B (fr) * 1991-11-25 1994-05-01 Sumitomo Chemical Co
US5599774A (en) * 1992-01-22 1997-02-04 Imperial Chemical Industries Plc N-arylindoles and their use as herbicides
US5395817A (en) * 1992-01-22 1995-03-07 Imperial Chemical Industries Plc N-arylindoles and their use as herbicides
AU665818B2 (en) * 1992-03-09 1996-01-18 Zeneca Limited Novel arylindazoles and their use as herbicides
US5444038A (en) * 1992-03-09 1995-08-22 Zeneca Limited Arylindazoles and their use as herbicides
EP0790057B1 (fr) * 1994-11-29 2002-06-05 Hisamitsu Pharmaceutical Co., Inc. Antibacterien et bactericide comprenant un derive de 2-aminothiazole et sels de ce derive
US6046136A (en) * 1997-06-24 2000-04-04 Zeneca Limited Herbicidal heterocyclic N-oxides compounds
US5840721A (en) * 1997-07-09 1998-11-24 Ontogen Corporation Imidazole derivatives as MDR modulators
AU732406B2 (en) * 1997-10-03 2001-04-26 Merck Frosst Canada & Co. Aryl thiophene derivatives as PDE IV inhibitors
CA2331118A1 (fr) * 1998-05-12 1999-11-18 Wyeth Acides oxazol-aryl-carboxyliques utiles dans le traitement de l'insulinoresistance et de l'hyperglycemie
AU5227999A (en) * 1998-07-27 2000-02-21 Abbott Laboratories Substituted oxazolines as antiproliferative agents
ES2317889T3 (es) * 2000-03-01 2009-05-01 Janssen Pharmaceutica Nv Derivados de tiazolilo 2,4-disustituido.

Also Published As

Publication number Publication date
WO2003027096A1 (fr) 2003-04-03
EP1432706A2 (fr) 2004-06-30
JP2005528325A (ja) 2005-09-22
WO2003027095A1 (fr) 2003-04-03
JP2005532983A (ja) 2005-11-04
AU2002340010A1 (en) 2003-04-07
WO2003027094A2 (fr) 2003-04-03
CA2461360A1 (fr) 2003-04-03
EP1432698A2 (fr) 2004-06-30
WO2003027105A1 (fr) 2003-04-03
WO2003027094A3 (fr) 2003-10-23
WO2003027085A3 (fr) 2003-12-04
WO2003027101A1 (fr) 2003-04-03
WO2003027100A1 (fr) 2003-04-03
WO2003027107A1 (fr) 2003-04-03
WO2003027085A2 (fr) 2003-04-03
AU2002362603A1 (en) 2003-04-07

Similar Documents

Publication Publication Date Title
CA2461363A1 (fr) 3-pyridyl indoles et indazoles substitues servant d'inhibiteurs de c17,20 lyase
US20040236110A1 (en) Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors
US20040198773A1 (en) Substituted 3-pyridyl oxazoles as c17,20 lyase inhibitors
JP6602470B2 (ja) Ｍｄｍ２−ｐ５３阻害薬としてのスピロ［３ｈ−インドール−３，２‘−ピロリジン］−２（１ｈ）−オン化合物及び誘導体
JP6503386B2 (ja) ＭＤＭ２−ｐ５３阻害剤としての新しいスピロ［３Ｈ−インドール−３，２’−ピロリジン］−２（１Ｈ）−オン化合物および誘導体
CN104812389B (zh) 某些化学实体、组合物及方法
JP6488367B2 (ja) ベンゾイミダゾール誘導体
BR112016022060B1 (pt) Composto, processo para preparação de um composto, composição farmacêutica, e, uso de um composto
BRPI0619517A2 (pt) ácidos pirazolo[1,5-a]piridina-3-carboxìlicos como inibidores de ephb e vegfr2 cinase
BR112015023279B1 (pt) compostos para inibição de fasn
BR112014029709B1 (pt) Composto, composição farmacêutica, combinação, produto, e, uso de um composto
JP2011510058A (ja) Ｃ−ｍｅｔの阻害剤として活性な縮合ピリジン
PT2318389E (pt) Derivados de piridazina como inibidores de smo
JP2013523614A (ja) Ｂ−ｒａｆキナーゼインヒビター
EP2598481A1 (fr) Composés de sulfonamide utiles en tant qu'inhibiteurs de cyp17
US20040267017A1 (en) 3-pyridyl or 4-isoquinolinyl thiazoles as c17, 20 lyase inhibitors
US9266880B2 (en) Substituted azaindazole compounds
CN112673009A (zh) 被取代的三唑并喹喔啉衍生物
EP1556382A1 (fr) Derives de pyridoindolone substitues en -3 par un phenyle, leur preparation et leur application en therapeutique.
JP2013542202A (ja) Ｃｙｐ１７修飾因子として有用である置換ベンゾイミダゾールおよびイミダゾピリジン化合物
US20040209924A1 (en) Substituted 3-pyridyl imidazoles as c17,20 lyase inhibitors
US20120095055A1 (en) HEXAHYDROCYCLOPENTYL[f]INDAZOLE 5-HYDROXYMETHYL ETHANOLS AND DERIVATIVES THEREOF AS SELECTIVE GLUCOCORTICOID RECEPTOR MODULATORS
KR20240035515A (ko) 삼중 고리 테트라하이드로 이소퀴놀린계 유도체의 염의 형태
WO2024074497A1 (fr) Composé inhibiteur de parg
CN116848103A (zh) 高活性hpk1激酶抑制剂

Legal Events

Date Code Title Description
FZDE Dead